Results 151 to 160 of about 187,458 (237)

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia

Journal of Blood Medicine, 2019
Aristea-Maria Papanota,* Ioannis Ntanasis-Stathopoulos,* Efstathios Kastritis, Meletios A Dimopoulos, Maria GavriatopoulouDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital,
Papanota AM, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA, Gavriatopoulou M   +4 more
doaj  

Bruton's tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy. [PDF]

Ann Med Surg (Lond)
Hujjat SFZ, Chandani HK, Khan MS, Chandani DK, Mahmoud A.   +4 more
europepmc   +1 more source

A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]

Front Immunol
Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z, Fan G, Lou Y.   +7 more
europepmc   +1 more source

Next-generation Bruton's tyrosine kinase inhibitors for chronic lymphocytic leukemia-associated membranoproliferative glomerulonephritis: a case report. [PDF]

Ann Hematol
Chen L, Huang Y, Xu J, Huang S, Zhang Q, Hua F, Pan X, Mi JQ.   +7 more
europepmc   +1 more source

Cryptococcal Infection in a Patient With Chronic Lymphocytic Leukaemia Receiving Acalabrutinib, a Bruton's Tyrosine Kinase Inhibitor: A Case Report. [PDF]

Cureus
Al-Shaker AN, Agarwal A, Saeed MT, Marney Z.   +3 more
europepmc   +1 more source

Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study. [PDF]

Cureus
Naseem A, Pednekar A, Patil S, Barkate H.   +3 more
europepmc   +1 more source

Spleen and Bruton's tyrosine kinase inhibitors for the management of adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials. [PDF]

Clin Hematol Int
Vatvani AD, Hariyanto TI, Ramirez AC, Shabarek N.   +3 more
europepmc   +1 more source

Comparison of One-Year Adverse Events Between First- and Second-Generation Bruton's Tyrosine Kinase Inhibitors: A Retrospective Study. [PDF]

Cureus
Ito A, Ito K, Iriyama C, Goto N, Inamoto Y, Okamoto M, Hirose Y, Morisaku M, Yamada S, Hayakawa N, Tomita A.   +10 more
europepmc   +1 more source

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.

Cancer Research, 2016
Andrew Stiff, P. Trikha, R. Wesolowski, K. Kendra, Vincent Hsu, Sarvani Uppati, Elizabeth L. McMichael, Megan C. Duggan, Amanda R. Campbell, Karen A. Keller, I. Landi, Y. Zhong, J. Dubovsky, J. H. Howard, Lianbo Yu, Bonnie K. Harrington, M. Old, S. Reiff, T. Mace, S. Tridandapani, N. Muthusamy, M. Caligiuri, J. Byrd, W. Carson   +23 more
semanticscholar   +1 more source

The new Bruton's tyrosine kinase inhibitors SPA8007 and SPA8009 reduce stemness and invasiveness of patient-derived glioblastoma tumorspheres. [PDF]

Transl Oncol
Jo E, Lee E, Oh Y, Lee D, Lee B, Kim K, Choi RJ, Hong J, Jeon Y, Cho H, Choi YS, Kim S, Won SY, Choi S, Roh TH, Moon JH, Kim EH, Chang JH, Jeon R, Kang SG.   +19 more
europepmc   +1 more source